Simplified Chinese
Another National-Level Recognition! Minhai Biotechnology Has Been Awarded the Title of “National Intellectual Property Demonstration Enterprise”
Release date:
2024-01-05
Author:
Source:
Abstract
Recently, the National Intellectual Property Administration issued the “Notice of the National Intellectual Property Administration on Designating the New Batch of 2023 and the Re‑certified National Intellectual Property Demonstration Enterprises and Advantageous Enterprises.” Beijing Minhai Biotechnology Co., Ltd. has been recognized as a “National Intellectual Property Demonstration Enterprise.”
Image source: Website of the National Intellectual Property Administration
A national intellectual property demonstration enterprise is one that embodies a strategic approach to IP management, demonstrates well-rounded capabilities in IP creation, utilization, protection, and administration, possesses distinct comprehensive competitive advantages in the field of intellectual property, and serves as a benchmark with significant industry influence. It is the highest honor and recognition bestowed by the state on enterprises for their intellectual property management.
In recent years, Minhai Biotechnology has placed great emphasis on intellectual property protection, strictly complied with relevant laws and regulations such as the Patent Law of the People’s Republic of China and the Trademark Law of the People’s Republic of China, and continuously improved its systems. Enterprise Intellectual Property Management System , ensuring that the intellectual property rights it owns are lawful and valid, and continuously strengthening the company’s core competitiveness.
Looking ahead, Minhai Biologics will continue to leverage its diversified R&D platforms, relentlessly break through cutting-edge technological barriers, and strive to develop more vaccine products with independent intellectual property rights, thereby contributing to the protection of global public health.
Recently, the National Intellectual Property Administration issued the “Notice of the National Intellectual Property Administration on Designating the New Batch of 2023 and the Re‑certified National Intellectual Property Demonstration Enterprises and Advantageous Enterprises.” Beijing Minhai Biotechnology Co., Ltd. has been recognized as a “National Intellectual Property Demonstration Enterprise.”
Image source: Website of the National Intellectual Property Administration
A national intellectual property demonstration enterprise is one that embodies a strategic approach to IP management, demonstrates well-rounded capabilities in IP creation, utilization, protection, and administration, possesses distinct comprehensive competitive advantages in the field of intellectual property, and serves as a benchmark with significant industry influence. It is the highest honor and recognition bestowed by the state on enterprises for their intellectual property management.
In recent years, Minhai Biotechnology has placed great emphasis on intellectual property protection, strictly complied with relevant laws and regulations such as the Patent Law of the People’s Republic of China and the Trademark Law of the People’s Republic of China, and continuously improved its systems. Enterprise Intellectual Property Management System , ensuring that the intellectual property rights it owns are lawful and valid, and continuously strengthening the company’s core competitiveness.
Looking ahead, Minhai Biologics will continue to leverage its diversified R&D platforms, relentlessly break through cutting-edge technological barriers, and strive to develop more vaccine products with independent intellectual property rights, thereby contributing to the protection of global public health.
Recently, the National Intellectual Property Administration issued the “Notice of the National Intellectual Property Administration on Designating the New Batch of 2023 and the Re‑certified National Intellectual Property Demonstration Enterprises and Advantageous Enterprises.” Beijing Minhai Biotechnology Co., Ltd. has been recognized as a “National Intellectual Property Demonstration Enterprise.”
Image source: Website of the National Intellectual Property Administration
A national intellectual property demonstration enterprise is one that embodies a strategic approach to IP management, demonstrates well-rounded capabilities in IP creation, utilization, protection, and administration, possesses distinct comprehensive competitive advantages in the field of intellectual property, and serves as a benchmark with significant industry influence. It is the highest honor and recognition bestowed by the state on enterprises for their intellectual property management.
In recent years, Minhai Biotechnology has placed great emphasis on intellectual property protection, strictly complied with relevant laws and regulations such as the Patent Law of the People’s Republic of China and the Trademark Law of the People’s Republic of China, and continuously improved its systems. Enterprise Intellectual Property Management System , ensuring that the intellectual property rights it owns are lawful and valid, and continuously strengthening the company’s core competitiveness.
Looking ahead, Minhai Biologics will continue to leverage its diversified R&D platforms, relentlessly break through cutting-edge technological barriers, and strive to develop more vaccine products with independent intellectual property rights, thereby contributing to the protection of global public health.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account